CBRN Diagnostics Overview

Rodney Wallace
Chief, CBRN Diagnostics
HHS\ASPR\BARDA

Presentation at BARDA Industry Day
December 10, 2012
BARDA Mission

Support development and availability of countermeasures for CBRN threats, pandemic influenza, and emerging infectious diseases through advanced product development, stockpile acquisition/building, manufacturing infrastructure building, and product innovation.

Washington Office Center  Patriots Plaza II
Diagnostics is a Countermeasure when it informs care of individual casualties /patients with other countermeasures

Focus on Dx for Clinical Samples:

- Dx where results can be reported for individual patients where the information can change the quality of care
  - Clinical Laboratory Diagnostics
  - Point of Care Diagnostics
BARDA Diagnostics Intended Users

- **Primary Focus for Diagnostics**
  - Enhance local surge capability
    - Sentinel laboratories
    - Physicians Office Labs (POL)
    - Point of Care (POC) where feasible

- **Clinical Samples Only**
  - Dx results that provide information on the health condition of an individual casualty.
Diagnostics Instrument Strategy (All Threats)

• **Laboratory**
  — Leverage platforms widely placed in clinical labs (at the time of the incident) to inform routine healthcare.
  — Fund adaptation, if required, to allow utilization of existing products.

• **Point of Care**
  — Develop new platforms where existing platforms do not meet needs of ConOps.
  — Improve performance of existing platforms
BARDA Diagnostics Open Solicitations

- **CBRN BAA**
  - BARDA-CBRN-BAA-12-100-SOL-000011
  - Area of Interest #6
  - Minimum TRL 4
  - limited to Biodosimetry, Biodiagnostics in the future

- **Strategic Sciences Innovations BAA**
  - BARDA-BAA-12-100-SOL-00013
  - Area of Interest #4
  - Biomarker and Platform Development
  - No Minimum TRL

- **Influenza BAA**
  - BARDA-12-100-SOL-00018
  - Area of interest #3
  - Minimum TRL varies by sub-AOI, between 6-8
## Man-made and Natural Threats

<table>
<thead>
<tr>
<th>CBRN Treat</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rad/Nuc</td>
<td>6 Biodosimetry Contracts in process</td>
</tr>
<tr>
<td>Biothreat Agent</td>
<td>Finalizing Needs/ Initiating Biomarker Development</td>
</tr>
<tr>
<td>Chemical Agent</td>
<td>Awaiting Resources</td>
</tr>
</tbody>
</table>
## BARDA CBRN Biothreat Clinical Diagnostic Priorities

<table>
<thead>
<tr>
<th>Biothreat Agent</th>
<th>PHEMCE SIP 2007</th>
<th>CDC Cat</th>
<th>DOD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anthrax</td>
<td>✓</td>
<td>A</td>
<td>✓</td>
</tr>
<tr>
<td>Botulinum toxins</td>
<td>✓</td>
<td>A</td>
<td></td>
</tr>
<tr>
<td>Glanders &amp; Meloidosis</td>
<td>✓</td>
<td>B</td>
<td>✓</td>
</tr>
<tr>
<td>Filoviruses</td>
<td>✓</td>
<td>A</td>
<td>✓</td>
</tr>
<tr>
<td>Tularemia</td>
<td>✓</td>
<td>A</td>
<td>✓</td>
</tr>
<tr>
<td>Typhus</td>
<td>✓</td>
<td>B</td>
<td>✓</td>
</tr>
<tr>
<td>Smallpox</td>
<td>✓</td>
<td>A</td>
<td>✓</td>
</tr>
<tr>
<td>Plague</td>
<td>✓</td>
<td>A</td>
<td>✓</td>
</tr>
</tbody>
</table>

Smallpox

Botulinum

Interfacing with BARDA

- [www.hhs.gov/aspr/barda](http://www.hhs.gov/aspr/barda)
  - Program description, information, news, announcements
- [www.medicalcountermeasures.gov](http://www.medicalcountermeasures.gov)
  - Portal to BARDA
  - Register, request a meeting
  - Tech Watch
- [www.fedbizopps.gov](http://www.fedbizopps.gov)
  - Official announcements and detailed information about all government solicitations
  - [Rodney.Wallace@hhs.gov](mailto:Rodney.Wallace@hhs.gov)